JACC:ST段抬高型心梗患者应该选哪种冠脉支架?

2019-11-20 不详 MedSci原创

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。 本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。

本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复合事件。经过平均3年时间的随访,与裸金属支架(BMS)相比,紫杉醇、西罗莫司、依维莫司或生物膜支架的主要终点事件发生率明显更低,而佐他莫司洗脱支架和BMS相比主要终点事件发生率无明显差异。DES组内的主要终点事件发生率无明显差异。另外,与BMS和第一代DES相比,第二代DES的支架内血栓发生率明显更低。

研究结果显示,在ST段抬高型心梗患者中,药物洗脱支架在长期有效性方面要优于裸金属支架,而不同药物洗脱支架之间无明显差异。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-10-12 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 gdsun
  7. [GetPortalCommentsPageByObjectIdResponse(id=2049506, encodeId=8f602049506e4, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Aug 20 01:13:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651724, encodeId=ec361651e2481, content=<a href='/topic/show?id=42e0309693a' target=_blank style='color:#2F92EE;'>#冠脉支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30969, encryptionId=42e0309693a, topicName=冠脉支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=203d24257066, createdName=smallant2010, createdTime=Mon Mar 16 22:13:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854574, encodeId=3b5e18545e42f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 12 19:13:00 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024061, encodeId=6d432024061aa, content=<a href='/topic/show?id=0ee11686460' target=_blank style='color:#2F92EE;'>#ST段抬高型心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16864, encryptionId=0ee11686460, topicName=ST段抬高型心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Oct 13 06:13:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326400, encodeId=46b713264006f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423096, encodeId=483c1423096cb, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624423, encodeId=8d9416244232d, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Fri Nov 22 00:13:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 hyf035

相关资讯

Heart:严重三尖瓣反流伴充血性心衰患者的预后分析

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的

Nutri Metab Cardiovas:降低心衰风险、延长心血管疾病患者寿命,间歇性禁食益处多多!

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。

JACC:他汀类药物的使用与认知力下降不呈相关性

他汀类药物可能与记忆和认知力下降相关,本研究的目的旨在评估老年患者他汀类药物使用和记忆与认知力变化的相关性。本研究纳入分析了MAS研究中的1037名70-90岁的患者,经过6年时间的随访,发现相比于从未使用他汀类药物的患者,他汀类药物使用者的记忆和认知力无明显差异,观察期间他汀类药物的启动与减缓记忆衰退的速度有关。探索性分析发现,使用他汀类药物与心脏病和载脂蛋白Eε4携带者的特异性记忆测试表现减弱

盘点:JACC十一月第三期研究一览

1. 重复心脏磁共振对急性心梗患者预后价值研究DOI: 10.1016/j.jacc.2019.08.1061http://www.onlinejacc.org/content/74/20?current-issue=y心脏磁共振(CMR)被广泛应用在急性心梗(AM)的诊断上,CMR常会在6个月后复查一次以评估心梗的进展情况。然而,6个月CMR的临床和预后作用尚不清楚。本研究纳入分析了ITAM

AHA 2019丨COLCOT试验:COLchicine心血管结局试验

2019年11月16日,一年一度的美国心脏协会科学年会(AHA)在美国宾夕法尼亚州费城隆重启幕,来自世界各地的15000多名顶尖医生、科学家、心脏病专家、保健专业人员和其他人士参加本次会议,讨论心血管科学和医学的未来。来自加拿大蒙特利尔心脏研究所的Jean-Claude Tardif教授在第一场LBS专场中为大家揭晓了COLCOT试验的最新研究结果,COLCOT试验的结果将确定,用小剂量消炎药秋水

Eur Heart J:Alirocumab对急性冠脉综合征患者心血管预后的影响

由此可见,在新近的ACS患者中,Alirocumab可改善患者结局,且与年龄无关。这表明降低LDL-C是ACS老年患者重要的预防干预措施。